Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ACADEMIA
ACADEMIA
- Concomitant Insulin a Must for Suglat Use in Type 1 Diabetes: Specialist
January 18, 2019
- 8-Week Treatment with Maviret a Promising First-Line Option for Hepatitis C: Hepatologist
January 11, 2019
- Tokyo Medical and Dental Univ. to Launch Investigator-Led Trial for JAK Inhibitor for CAEBV
January 10, 2019
- Health Economist Calls for Robust Appraisal Process in Japan CEA System
November 20, 2018
- Hematology Specialist Advises Caution in Using Hemlibra in Children
October 30, 2018
- Research Group Builds New Pathogenic Variants Database for Japanese Hereditary Breast Cancer
October 16, 2018
- I/O Pioneers Win Nobel Prize in Medicine; Honjo Prods Japan Firms to Make More Academic Investment at Home
October 2, 2018
- New Treatment GL for Statin Intolerance Compiled by Atherosclerosis Society, 3 Other Academic Societies
October 1, 2018
- Opdivo Holds Promise as New Option for Malignant Pleural Mesothelioma: Pulmonary Specialist
September 21, 2018
- Oncologist Hails Tagrisso Approval for 1st-Line Lung Cancer Treatment
September 14, 2018
- Japan Cancer Association to Release Statement on Health Spending at Sept. Meeting
August 24, 2018
- Only 30% of Patients Took Thyroid Tests before Receiving Dementia Meds: Survey
July 25, 2018
- Debut of siRNA Therapeutic Looming on Horizon; Alnylam’s Patisiran Might Be Filed in Japan Too
July 24, 2018
- Japanese Society of Medical Oncology to Update I/O Guidelines in October
July 18, 2018
- Hematologist Optimistic about New Drugs for AML Including SMO and BCL-2 Inhibitors as Well as FLT3 Inhibitors
July 11, 2018
- Doctors Need Solid Understanding of Hereditary Cancer When Prescribing Lynparza for Breast Cancer: Prof.
July 5, 2018
- Anti-TNF-α Antibody Treatment for Crohn’s Disease Costs 1.95 Million Yen per Patient Annually: Study
June 27, 2018
- Licensee Selection Draws Near for AMED-Backed Cancer Mouth Sores Treatment
June 26, 2018
- Nucala, Fasenra to Be Ranked as Strongest Treatments in New Asthma Guidelines: Allergology Society
June 21, 2018
- MHLW Study Group to Discuss Roles of JAK Inhibitors and Biosimilars toward RA Treatment Guidelines Revision
June 5, 2018
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…